GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oryzon Genomics ORY.MC · EUR

Health Care · BME · 🇪🇸 Spain

Compare

2.38

+2.15%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Oryzon Genomics

Its shares trade on BME under the ticker ORY.MC. It has been listed since 10 December 2015. In the fiscal year to 31 December 2024, it reported revenue of €7.4m and a net loss of €3.7m. At that date it held total assets of €108.7m and shareholders' equity of €87.0m.

Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
10 Dec 2015
Employees
43
Website
oryzon.com ↗

Leadership

Pay as last reported

  • Don Carlos Manuel Buesa ArjolExecutive Chairman of the Board, Chief Executive Officer, since 2002€478,000
  • Don Enric Rello CondominesChief Financial and Operating Officer
  • Don Jordi Xaus PeyChief Scientific Officer
  • Don Xavier Perpinya RiberaChief Internal Audit and Compliance Officer
  • Dna. Sonia Paloma Gutierrez BezonDirector - Clinical Operations
  • Don Michael RopackiChief Medical Officer - CNS
  • Don Emili Torrell CortadaDirector - Business Development
  • Dna. Neus Virgili BernadoDirector - Intellectual Property
  • Don Augusto Pinel RubioNon-Member Secretary of the Board
  • Don Manuel Oscar Lopez-FigueroaLead Independent Director€65,000
  • Don Ramon Adell RamonIndependent Director€50,000
  • Dna. Isabel Aguilera NavarroIndependent Director€50,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
81
Environment
88
Social
99
Governance
56
Carbon reduction policy
No
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Oryzon Genomics SA has several key strengths that contribute to its competitive advantage:

Weaknesses

  • Despite its strengths, Oryzon Genomics SA also faces certain weaknesses:

Opportunities

  • Oryzon Genomics SA can capitalize on the following opportunities in the market:

Threats

  • Oryzon Genomics SA should be aware of the following threats in the competitive landscape:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.